Nipun Patel, MD
Internal Medicine · Chamblee, GANPI 1417990987
Payments from drug & device makers
Across 253 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$717
- Novo Nordisk$502
- Amgen$471
- GSK$439
- Bayer$380
- Lilly USA, LLC$375
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,886100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $717 |
| Novo Nordisk | 36 | $502 |
| Amgen | 22 | $471 |
| GSK | 24 | $439 |
| Bayer | 18 | $380 |
| Lilly USA, LLC | 21 | $375 |
| AbbVie(2 entities) | 22 | $365 |
| Shield Therapeutics Inc | 9 | $198 |
| Pfizer | 8 | $182 |
| Amarin Pharma, Inc. | 9 | $154 |
| Paratek Pharmaceuticals, Inc. | 8 | $146 |
| Xeris Pharmaceuticals, Inc. | 6 | $123 |
| Johnson & Johnson | 6 | $112 |
| Boehringer Ingelheim | 6 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $96 |
| Merck | 5 | $82 |
| Arbor Pharmaceuticals, Inc. | 2 | $64 |
| Exact Sciences | 3 | $58 |
| Astellas Pharma US Inc | 2 | $46 |
| Corcept Therapeutics | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Linus Health, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
| Redhill Biopharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,892 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tasimelteon | 11 | $225,535 |
| JardianceEmpagliflozin | 95 | $132,609 |
| OzempicSemaglutide | 77 | $128,285 |
| JanuviaSitagliptin Phosphate | 92 | $116,669 |
| ProliaDenosumab | 57 | $98,935 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $85,469 |
| EliquisApixaban | 61 | $62,996 |
| Teriparatide | 24 | $58,858 |
| ForteoTeriparatide | 13 | $52,900 |
| RybelsusSemaglutide | 18 | $49,366 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $38,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $32,169 |
| LinzessLinaclotide | 26 | $29,827 |
| XareltoRivaroxaban | 23 | $22,306 |
| FarxigaDapagliflozin Propanediol | 18 | $21,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $502 | $177,65195 claims |
| Boehringer IngelheimJardiance, Tradjenta | $103 | $148,997109 claims |
| MerckJanuvia, Janumet Xr | $82 | $131,452104 claims |
| AmgenProlia | $471 | $98,93557 claims |
| PfizerEliquis | $182 | $62,99661 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $717 | $60,04075 claims |
| Lilly USA, LLCForteo | $375 | $52,90013 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $439 | $48,19282 claims |
| AbbVieLinzess | $365 | $29,82726 claims |
| Johnson & JohnsonXarelto | $112 | $22,30623 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $8,23314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Chamblee
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.